You are here

  • Home
  • Archive
  • Volume 9, Issue 2
  • Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Article metrics

Article menu

This article has a correction. Please see:

Download PDFPDF

XML
Oncolytic and local immunotherapy
Original research
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

 

Online download statistics by month:

Online download statistics by month: February 2021 to February 2026

AbstractFullPdf
Feb 2021306306109
Mar 202120820871
Apr 202111911943
May 202115515575
Jun 202112512525
Jul 202112912924
Aug 202111511568
Sep 202116216238
Oct 202112512744
Nov 202116616754
Dec 202112112116
Jan 202211411829
Feb 2022929524
Mar 202214714937
Apr 202213614132
May 202218519241
Jun 202213313932
Jul 202212012424
Aug 202211511818
Sep 202211711729
Oct 2022969732
Nov 2022979822
Dec 2022727232
Jan 202310110328
Feb 202311811925
Mar 202311511727
Apr 2023849046
May 202310810824
Jun 202313913922
Jul 202312512520
Aug 202310010515
Sep 202310110822
Oct 202312112118
Nov 202316316330
Dec 202319119221
Jan 2024394055
Feb 202484849
Mar 202413113363
Apr 202415215238
May 202410410528
Jun 20249910120
Jul 202412813030
Aug 2024969612
Sep 2024969620
Oct 202414414417
Nov 202418218420
Dec 202415115324
Jan 202514915027
Feb 202517817818
Mar 202513613716
Apr 202512312317
May 2025767613
Jun 2025686913
Jul 2025110
Aug 2025110
Feb 2026110
Total676068381657